Eff ects of Ivacaft or in Patients with Cystic Fibrosis Who Carry the G551D mutation and have severe lung disease

Chest

Volumn 146, Issue 1, 2014, Pages 152-158

  Barry, Peter J ^a,b   Plant, Barry J ^c   Nair, Arjun ^d   Bicknell, Stephen ^e   Simmonds, Nicholas J ^d   Bell, Nicholas J ^f   Shafi, Nadia T ^g   Daniels, Thomas ^h   Shelmerdine, Susan ^d   Felton, Imogen ^d   Gunaratnam, Cedric ⁱ   Jones, Andrew M ^a   Horsley, Alex R ^a,j  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL COLLEGE OF PHYSICIANS OF IRELAND   (Ireland)

^c University College Cork and INFANT Centre   (Ireland)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^f Bristol Adult Cystic Fibrosis Centre   (United Kingdom)

^g PAPWORTH HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ BEAUMONT HOSPITAL   (Ireland)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HEMOGLOBIN A1C; IVACAFTOR; AMINOPHENOL DERIVATIVE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; N-(2,4-DI-TERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE; QUINOLONE DERIVATIVE;

ADULT; CASE CONTROL STUDY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; G551D GENE; GENE; GENE MUTATION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG DISEASE; LUNG TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNITED KINGDOM; ARTICLE; FOLLOW UP; GENETICS; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; LUNG DISEASES; MALE; MUTATION; QUINOLONES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84903829603     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2397     Document Type: Conference Paper

References (16)

1. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009; 106 (44): 18825-18830.
2. Accurso FJ, Rowe SM, Clancy JP, et al. Eff ect of VX-770 in persons with cystic fi brosis and the G551D-CFTR mutation. N Engl J Med. 2010; 363 (21): 1991-2003.
3. Cystic Fibrosis Foundation. C ystic Fibrosis Foundation Patient Registry. Bethseda, MA: Cystic Fibrosis Foundation; 2011.
4. UK Cystic Fibrosis Trust. U K Cystic Fibrosis Registry Annual Report. London, England: UK Cystic Fibrosis Trust; 2010.
5. Cystic Fibrosis Registry of Ireland. Cystic Fibrosis Registry of Ireland Annual Report. Dublin, Ireland: Cystic Fibrosis Registry of Ireland; 2011.
6. Davies JC, Wainwright CE, Canny GJ, et al; VX08-770-103 (ENVISION) Study Group. Effi cacy and safety of ivacaft or in patients aged 6 to 11 years with cystic fi brosis with a G551D mutation. Am J Respir Crit Care Med. 2013; 187 (11): 1219-1225.
7. Ramsey BW, Davies J, McElvaney NG, et al; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fi brosis and the G551D mutation. N Engl J Med. 2011; 365 (18): 1663-1672.
8. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fi brosis: cohort study from 1990 to 2007. BMJ. 2011;342:d1008.
9. Goss CH, Burns JL. Exacerbations in cystic fi brosis. 1: epide miology and pathogenesis. Thorax. 2007; 62 (4): 360-367.
10. Barry P, Plant B, Nair A, et al. UK and Ireland review of ivacaft or in severe CF: impact on lung function and weight. J Cyst Fibros. 2013; 12 (suppl): S15.
11. Barry P, Plant B, Simmonds NJ, et al. UK and Ireland review of Ivacaft or in severe CF: impact on hospitalisations and antibiotic use. J Cyst Fibros. 2013; 12 (suppl): S62.
12. Horsley AR, Davies JC, Gray RD, et al. Changes in physiological, functional and structural markers of cystic fi brosis lung disease with treatment of a pulmonary exacerbation. Thorax. 2013; 68 (6): 532-539.
13. Bush A, Simmonds NJ. Hot off the breath: 'I've a cost for'the 64 million dollar question. Thorax. 2012; 67 (5): 382-384.
14. Clancy JP, Jain M. Personalized medicine in cystic fi brosis: dawning of a new era. Am J Respir Crit Care Med. 2012; 186 (7): 593-597.
15. Altes T, Johnson M, Mugler J, et al. The eff ect of ivacaft or, an investigational CFTR potentiator, on hyperpolarized noble gas magnetic resonance imaging in subjects with cystic fi brosis who have the G551D-CFTR mutation. Am J Respir Crit Care Med. 2012; 185 (meeting abstracts): A2814.
16. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002; 121 (1): 64-72.